Updated

Kura Oncology is pivoting its diabetes-related drug strategy into a new $50 million subsidiary, according to new reporting. The move reflects an effort to isolate and separately fund a specific therapeutic program outside the company's core oncology-focused pipeline. The restructuring highlights how biotech companies are increasingly using subsidiary structures to manage capital allocation across diverse drug-development programs.